Resumen de SEOM clinical guidelines for cervical cancer (2019)

Ana de Juan Ferré, A. Redondo Sánchez, María Jesús Rubio Pérez, Yolanda García García, J. F. Cueva Bañuelos, Lydia Gaba, Alfonso Yubero Esteban, Jesús Damian Alarcón Company, C. Maximiano Alonso, Ana Oaknin

• Cervical cancer (CC) is the fourth most common cancer in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income countries, the screening programs have dramatically decreased the incidence of CC; however, the lack of accessibility to them in developing countries makes CC an important cause of mortality. Clinical stage is the most relevant prognostic factor in CC. The new FIGO staging system published in 2018 is more accurate than the previous one since it takes into account the lymph node status. In early stages, the primary treatment is surgery—with some concerns recently raised regarding minimally invasive surgery because it might decrease survival—or radiotherapy, whereas concomitant chemo-radiotherapy is the conventional approach in locally advanced stages. For recurrent or metastatic CC, the combination of chemotherapy plus bevacizumab is the preferred therapy. Immunotherapy approach based on checkpoint inhibitors is evolving as the election therapy following failure to platinum therapy.